Daniel Morgenstern
The Hospital for Sick Children · The Hospital for Sick Children - Canadian Study Chair
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Morgenstern as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:28 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06519682 · A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)Daniel Morgenstern · recruiting · High Grade Glioma, Replication Repair Deficient · study director
- Early Ph1NCT06381570 · Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade GliomasDaniel Morgenstern · recruiting · Low-grade Glioma · study director
- Ph1/Ph2NCT06208657 · Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerAustralian & New Zealand Children's Haematology/Oncology Group · recruiting · Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor · study chair
- Ph1NCT03206021 · COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid TumorsThe Hospital for Sick Children · completed · Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood, Childhood Solid Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:28 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- 189 citationsRCR 6.6
- 168 citationsRCR 4.9
- Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.Nat Med · 2023122 citationsRCR 11.1
- Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.J Clin Pharmacol · 200963 citationsRCR 1.5
- Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.Future Oncol · 201855 citationsRCR 1.7
- The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.Nat Commun · 202534 citationsRCR 8.4
- 33 citationsRCR 1.0
- Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.Pediatr Blood Cancer · 201427 citationsRCR 0.8
- Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.JAMA Oncol · 202427 citationsRCR 3.5
- Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.Eur J Cancer · 202122 citationsRCR 1.3